Johannes Müthing


Country: Germany


  1. Pohlentz G, Steil D, Rubin D, Mellmann A, Karch H, Muthing J. Pectin-derived neoglycolipids: Tools for differentiation of Shiga toxin subtypes and inhibitors of Shiga toxin-mediated cellular injury. Carbohydr Polym. 2019;212:323-333 pubmed publisher
    ..The produced neoGLs are applicable for differentiation of Stx subtypes and represent a promising approach to combat infections of EHEC by blocking their major toxins. ..
  2. Legros N, Pohlentz G, Steil D, Muthing J. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells. Int J Med Microbiol. 2018;308:1073-1084 pubmed publisher
    ..Increasing knowledge on the precise initial molecular mechanisms by which Stxs interact with cellular targets will help to develop specific therapeutics and/or preventive measures to combat EHEC-caused diseases. ..
  3. Legros N, Pohlentz G, Steil D, Kouzel I, Liashkovich I, Mellmann A, et al. Membrane assembly of Shiga toxin glycosphingolipid receptors and toxin refractiveness of MDCK II epithelial cells. J Lipid Res. 2018;59:1383-1401 pubmed publisher
    ..The results suggest that the cellular content of Stx receptor GSLs and their biochemical detection in DRM preparations alone are inadequate to predict cellular sensitivity toward Stxs. ..
  4. request reprint
    Muthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U, et al. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J. 2005;19:103-5 pubmed
    ..This strict binding specificity of rViscumin and the increased expression of CD75s gangliosides in various tumors suggest this anticancer drug as a promising candidate for an individualised adjuvant therapy of human tumors. ..
  5. Muthing J, Distler U. Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry. Mass Spectrom Rev. 2010;29:425-79 pubmed publisher
    ..The combination of these two supplementary techniques opens new doors by delivering specific structural information of trace quantities of GSLs with only limited investment in sample preparation. ..
  6. Steil D, Schepers C, Pohlentz G, Legros N, Runde J, Humpf H, et al. Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment. J Lipid Res. 2015;56:2322-36 pubmed publisher
    ..This study provides the basis for further exploring the functional impact of lipid raft-associated Stx receptors for toxin-mediated injury of Vero-B4 cells. ..
  7. request reprint
    Muthing J, Schweppe C, Karch H, Friedrich A. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 2009;101:252-64 pubmed
    ..This approach may be helpful to gain insights into Stx-induced impairment of target cells that is suggested to originate at least partly from the structural heterogeneity of the cellular ligands of Stxs. ..
  8. Muthing J, Meisen I, Zhang W, Bielaszewska M, Mormann M, Bauerfeind R, et al. Promiscuous Shiga toxin 2e and its intimate relationship to Forssman. Glycobiology. 2012;22:849-62 pubmed publisher
  9. Betz J, Dorn I, Kouzel I, Bauwens A, Meisen I, Kemper B, et al. Shiga toxin of enterohaemorrhagic Escherichia coli directly injures developing human erythrocytes. Cell Microbiol. 2016;18:1339-48 pubmed publisher
    ..The observed Stx-mediated toxicity towards erythroblasts during the course of erythropoiesis might contribute, although speculative at this stage of research, to the anaemia caused by Stx-producing pathogens. ..

More Information


  1. Legros N, Dusny S, Humpf H, Pohlentz G, Karch H, Müthing J. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells. Glycobiology. 2017;27:99-109 pubmed publisher
  2. request reprint
    Muthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H, et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry. 2004;43:2996-3007 pubmed
    ..This strict preference might help to explain the immunostimulatory potential of ML-I toward certain leukocyte subpopulations and its therapeutic success as a cytotoxic anticancer drug...
  3. Steil D, Bonse R, Meisen I, Pohlentz G, Vallejo G, Karch H, et al. A Topographical Atlas of Shiga Toxin 2e Receptor Distribution in the Tissues of Weaned Piglets. Toxins (Basel). 2016;8: pubmed
  4. Kouzel I, Pohlentz G, Schmitz J, Steil D, Humpf H, Karch H, et al. Shiga Toxin Glycosphingolipid Receptors in Human Caco-2 and HCT-8 Colon Epithelial Cell Lines. Toxins (Basel). 2017;9: pubmed publisher
    ..Collectively, Caco-2 and HCT-8 cells express a plethora of different receptor lipoforms and are susceptible towards Stx2a exhibiting somewhat lower sensitivity when compared to Vero cells. ..